Compare · NVO vs XTLB
NVO vs XTLB
Side-by-side comparison of Novo Nordisk A/S (NVO) and XTL Biopharmaceuticals Ltd. (XTLB): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both NVO and XTLB operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- NVO is the larger of the two at $220.35B, about 9089.4x XTLB ($24.2M).
- NVO has hit the wire 5 times in the past 4 weeks while XTLB has been quiet.
- NVO has more recent analyst coverage (25 ratings vs 0 for XTLB).
- Company
- Novo Nordisk A/S
- XTL Biopharmaceuticals Ltd.
- Price
- $41.18+6.93%
- $2.52+3.48%
- Market cap
- $220.35B
- $24.2M
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NYSE
- NASDAQ
- IPO
- News (4w)
- 5
- 0
- Recent ratings
- 25
- 0
Novo Nordisk A/S
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Lund University to develop treatment for Parkinson's diseases; and bluebird bio, Inc. to develop genome editing treatments for children and adult patients. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
XTL Biopharmaceuticals Ltd.
XTL Biopharmaceuticals Ltd., a biopharmaceutical company, engages in the acquisition and development of pharmaceutical products for the treatment of autoimmune diseases. Its lead drug candidate is hCDR1, a Phase II-ready asset for the treatment of systemic lupus erythematosus and Sjogren's syndrome. XTL Biopharmaceuticals Ltd. has a licensing agreement with Yeda Research and Development Company Limited for the research, development, and commercialization of hCDR1 for various indications. The company was formerly known as Xenograft Technologies Ltd. and changed its name to XTL Biopharmaceuticals Ltd. in July 1995. XTL Biopharmaceuticals Ltd. was incorporated in 1993 and is headquartered in Ramat Gan, Israel.
Latest NVO
- The Longevity Trade Is No Longer a Buzzword — It's a $120 Billion Market, and the FDA Just Cleared the First Cellular Rejuvenation Trial
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- Wolfe Research initiated coverage on Novo Nordisk A/S
Latest XTLB
- SEC Form 3 filed by new insider Segal Niv
- SEC Form 3 filed by new insider Hillel Fain Osnat
- SEC Form 6-K filed by XTL Biopharmaceuticals Ltd.
- XTL Biopharmaceuticals Announces ADS Ratio Change
- SEC Form 6-K filed by XTL Biopharmaceuticals Ltd.
- SEC Form 6-K filed by XTL Biopharmaceuticals Ltd.
- XTL Announces Receipt of Staff Delist Determination from Nasdaq and Plans to Request Hearing
- SEC Form 6-K filed by XTL Biopharmaceuticals Ltd.
- SEC Form 6-K filed by XTL Biopharmaceuticals Ltd.
- SEC Form 6-K filed by XTL Biopharmaceuticals Ltd.